Short-chain fatty acids · Stool test

Short-Chain Fatty Acids: Why a Fecal Panel Misleads

Short-chain fatty acids on a fecal panel are residue, not production: colonocytes absorb 95% of what fermentation makes, so the stool value reads the 5% left over. That number supports no deficiency diagnosis and no dose.

Patients arrive with a flagged butyrate result and a supplement already started. The assay reads what the epithelium did not absorb, which makes it the wrong input for a management decision.

Short-chain fatty acids reach the exam room on direct-to-consumer stool reports, usually with butyrate flagged low and a capsule already bought. The defensible response is not to argue about the supplement but to say what the assay sampled, then measure something that changes management.

The chapter video, Full of Calories, Starving One Cell Deep, presents chapter 14 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. Trial-level numbers, with the limits of each study, sit in the book’s Deep Dive companion. Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service and performs no stool, breath or endoscopic studies.

What does a fecal short-chain fatty acid test measure?

Colonocytes absorb 95% of what fermentation produces, leaving 5% to exit in stool, which is the fraction any fecal assay reads. Systemic availability measured with labeled substrate delivered into the human colon runs 2% for butyrate, 9% for propionate and 36% for acetate. Butyrate is a local fuel consumed at the epithelium, not a circulating hormone.

The measurement rule follows directly: a fecal concentration is residue, not production. A low value is equally consistent with efficient absorption, and production estimates themselves carry spreads nearly as large as the point estimate. Nothing in that report supports a deficiency diagnosis or a dose.

Does butyrate supply 70% of colon cell energy?

Dr. Padda taught the line that butyrate supplies 70% of colonocyte energy for years before reading the 1980 source, and says so plainly. That experiment used colonocyte suspensions from 14 operative specimens: butyrate accounted for 73% of oxygen consumption in ascending and 75% in descending colon, falling to 59% and 72% when physiological glucose was present. The endpoint was oxygen consumption in a dish. No equivalent measurement exists in a living human, and the correct restatement is more than 70% of the oxygen consumed by colonic epithelium.

The patient in whom this matters

The presenting picture is loose stools for years, a normal colonoscopy, biopsies reported as mild nonspecific changes, and a diet with almost nothing fermentable in it. Two prescriptions usually sit alongside. Among 1,815 people, 211 of them taking a proton pump inhibitor, use was associated with reduced diversity and change in 20% of bacterial taxa, which the authors judged more prominent at population level than antibiotics.

The combination has one randomized human test. Small-bowel injury on capsule endoscopy appeared in 44.4% of volunteers given an acid blocker with an anti-inflammatory against 16.7% on placebo, a relative risk of 2.67 with an interval of 1.08 to 6.58, and the lesions were jejunal in 26% of the treated group. Healthy young volunteers, two weeks, a surrogate endpoint. It remains the only trial of a pairing carried by millions of patients.

Three drivers converge, and only two are biological: fermentable substrate absent from the plate, an acid-suppressed and reshaped luminal community, and a review structure in which a renewal takes seconds while reconsidering the indication takes a visit nobody books. The agricultural incentive that fills the plate with acellular carbohydrate is the same one that empties it of fermentable fiber.

Which has the evidence, fiber or a butyrate supplement?

Dietary fiber, not a metabolite in a capsule, carries the outcome evidence. Across 185 prospective studies and 58 clinical trials, higher fiber intake tracked with 15-30% lower all-cause and cardiovascular mortality, and the band of greatest benefit ran from 25 g to 29 g daily. For constipation, fiber produced response in 66% against 41% on control, a relative risk of 1.48 with an interval of 1.17 to 1.88, an effect carried by psyllium and pectin above 10 g a day.

Counsel the predictable adverse effect in advance. In irritable bowel syndrome prebiotics performed numerically worse than placebo, 54% against 63%, and inulin-type fructans significantly worsened flatulence. Imaged directly, 20 g of inulin produced a colonic gas area under the curve of 3145 mL.min, cut to 618 by co-administered psyllium. Habitual intake predicts response: established high-fiber eaters gained the major butyrate producer while low-fiber eaters did not, which inverts how these products are marketed.

Oral and rectal butyrate do not substitute. Four grams daily for a month in 30 adults with longstanding type 1 diabetes raised fecal butyrate and changed no prespecified outcome. Enema trials pooled across eight randomized studies and 227 patients showed no endoscopic or histologic separation from control.

What to measure instead

Stool short-chain fatty acid panels, breath testing and endoscopy are studies performed elsewhere. What can be added to this workup is the metabolic terrain the bowel sits in, reported back to the ordering physician:

• Laboratory panels for current glycemic, lipid and inflammatory markers, which is where metaflammation becomes a number rather than an adjective.
• Bioimpedance body composition to separate fat from lean mass in a patient whose weight has been stable through years of symptoms.
• Indirect calorimetry for measured resting energy expenditure when fatigue has been attributed to age or to the bowel by default.

Prevalence justifies a low threshold to test: on NHANES 2009-2016 under 12.2% of US adults were metabolically healthy, and under 7% under the tighter post-2021 criteria.

Standing orders, workflow and documentation

A standing order attaching a laboratory panel and body composition measurement to patients on chronic acid suppression with persistent bowel symptoms removes the decision from the individual encounter, which is the only way the longitudinal record gets built. Results filed as discrete data in the chart stay visible when the next refill request appears. The same values populate diabetes and body mass index measures practices already report through MIPS and quality reporting, which is a documentation benefit and never an indication on its own.

Where the evidence stops

The oxygen mechanism is mouse and cell work; no one has held a probe against living human epithelium for a week. In inflamed tissue the defect is transport, not combustion, since the butyrate transporter is downregulated by interferon-gamma and tumor necrosis factor-alpha, and across 207 people oxidation was impaired only in endoscopically active disease. And the treatment that heals pediatric Crohn’s mucosa better than steroids, at a relative risk of 2.36 with an interval of 1.22 to 4.57, is a fiber-poor formula under which fecal butyrate falls. That paradox is unresolved and stated as such.

The practice position is unchanged by it: feed the producers, revisit the prescriptions, and measure the terrain rather than the residue. The patient-facing version of the same argument is what a flagged butyrate result really samples.

Frequently asked questions

References

• den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research, 54(9), 2325-2340. https://doi.org/10.1194/jlr.R036012
• Boets, E., Gomand, S. V., Deroover, L., Preston, T., Vermeulen, K., De Preter, V., Hamer, H. M., Van den Mooter, G., De Vuyst, L., Courtin, C. M., Annaert, P., Delcour, J. A., & Verbeke, K. A. (2017). Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. The Journal of physiology, 595(2), 541-555. https://doi.org/10.1113/JP272613
• Roediger, W. E. (1980a). Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut, 21(9), 793-798. https://doi.org/10.1136/gut.21.9.793
• Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J., Dijkstra, G., Franke, L., Xavier, R. J., Jonkers, D., Wijmenga, C., Weersma, R. K., & Zhernakova, A. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740-8. https://doi.org/10.1136/gutjnl-2015-310376
• Washio, E., Esaki, M., Maehata, Y., Miyazaki, M., Kobayashi, H., Ishikawa, H., Kitazono, T., & Matsumoto, T. (2016). Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: A randomized, placebo-controlled trial. Clinical gastroenterology and hepatology, 14(6), 809-815.e1. https://doi.org/10.1016/j.cgh.2015.10.022
• Reynolds, A., Mann, J., Cummings, J., Winter, N., Mete, E., & Te Morenga, L. (2019). Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet (London, England), 393(10170), 434-445. https://doi.org/10.1016/S0140-6736(18)31809-9
• van der Schoot, A., Drysdale, C., Whelan, K., & Dimidi, E. (2022). The effect of fiber supplementation on chronic constipation in adults: An updated systematic review and meta-analysis of randomized controlled trials. The American journal of clinical nutrition, 116(4), 953-969. https://doi.org/10.1093/ajcn/nqac184
• de Groot, P. F., Nikolic, T., Imangaliyev, S., Bekkering, S., Duinkerken, G., Keij, F. M., Herrema, H., Winkelmeijer, M., Kroon, J., Levin, E., Hutten, B., Kemper, E. M., Simsek, S., Levels, J. H. M., van Hoorn, F. A., Bindraban, R., Berkvens, A., Dallinga-Thie, G. M., Davids, M., … Nieuwdorp, M. (2020). Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. Diabetologia, 63(3), 597-610. https://doi.org/10.1007/s00125-019-05073-8
• Thibault, R., De Coppet, P., Daly, K., Bourreille, A., Cuff, M., Bonnet, C., Mosnier, J.-F., Galmiche, J.-P., Shirazi-Beechey, S., & Segain, J.-P. (2007). Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology, 133(6), 1916-1927. https://doi.org/10.1053/j.gastro.2007.08.041
• Ding, Z., Ninan, K., Johnston, B. C., Moayyedi, P., Sherlock, M., & Zachos, M. (2023). Microbiota signatures and mucosal healing in the use of enteral nutrition therapy versus corticosteroids for the treatment of children with Crohn’s disease: A systematic review and meta-analysis. The British Journal of Nutrition, 130(8), 1385-1402. https://doi.org/10.1017/S0007114523000405

Related reading

• Psychogastroenterology in Practice: Measuring the Autonomic Side
• Ultra-Processed Food: Measure the Host, Not the Additive
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.